Nonunion bone fracture is changeless disappointment of recuperating following a broken bone unless intercession, (for example, surgery) is performed. Nonunion fractures can be categorized into hypertrophic (generally due to mechanical failure/ callus formation) and atrophic (generally due to organic failure/ no callus and bone resorption). A delayed or with nonunion fracture forms a structural resemblance to a fibrous joint, and is therefore often called pseudoarthrosis. Nonunion fracture is a genuine complexity of a bone fracture and may happen when the bone moves excessively, has a poor blood supply or gets infected. Patients who smoke have a higher occurrence of nonunion fractures. The ordinary procedure of bone recuperating is hindered or slowed down. A nonunion or delayed fracture may go ahead to recuperate without mediation in many cases. In normal, if a nonunion is as yet obvious at a half year post damage it will stay unhealed without particular treatment, generally orthopedic surgery. The revision surgical intervention is the common methodology utilized, treatment via stem cell therapies is also on a rise, such as, Regenexx stem cell procedure. The explanations for a non-union fracture may comprise: complicated, multisegmental fractures (severe comminution), open fractures, fractures associated with tumors (pathologic fractures), infection, inadequate fracture immobilization (fixation), inadequate blood supply, poor nutrition, and chronic disease states (diabetes, renal failure, metabolic bone disease).
Factors Driving Non-union fractures
Increasing sports related injuries and mechanical injuries, diabetic population, obesity, bone infection, poor nutrition and rising pathologic fractures among geriatric individuals is going to spur revenue growth for global non-union fractures market. In the US, there are roughly seven million new fractures which occur every year, with around 300,000 growing gradually. Appraisals for the normal non-union fracture associated treatment cost shift from almost $25,000 to $45,000. Non-unions are assessed to cost the healthcare services in the US $9.2 billion/year. This prohibits losses in profitability to the economy.
Rising Associated Cost for Non-union fractures Treatment
In the UK, there are around 850,000 new bone fractures seen every year. While it has been recommended that roughly 5-10% of such fractures are fractures in which the broken bone neglects to recuperate, medicinally alluded to as nonunion bone fractures. The cost to the National Health Service of treating non-union bone fractures has been accounted for to go amongst £18,000 and £79,000 per individual. The evaluated addressable market for nonunion and improved recuperating of bone fractures for the EU is around 0.7 to 2 Bn Euros for each year, expecting a cost of roughly 2,000 to 2,500 Euro for every treatment regimen. Normal direct expenses of treatment for a built up long bone non-union have been accounted for: Canada, $11,800; the USA $11,333; the UK £29,204.
By Treatment Type
Regional Market Outlook
Globally, around 50 Mn bone fractures occur worldwide consistently. Osteoporosis is the most widely recognized reason for bone fractures and the commonness of osteoporosis and low bone mass is required to increment in coming a very long time due basically to the geriatric and matured population. Roughly 33% of all tibia and femoral shaft bone fractures have deferred rates of recuperating or non-healing. Patients with postponed union or non-union can expect poorer results, including expanded pain, loss of overall functionality, loss of personal satisfaction, and deferral consequently to work. There are as of now restricted treatment alternatives accessible for enhancing the rate of bone healing and bone fracture repair. Anabolic specialists and bone morphogenetic proteins, including teriparatide, are exorbitant and may need wanted viability; enhanced therapeutic or remedial choices are desired. On the basis of geography, the global non-union fractures market can be segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America and Europe collectively are expected to dominate the global non-union fractures market due to increasing awareness and inclination of treatment options coupled with stem cell therapy management. However, APAC is expected to grow at a sluggish rate in the global market due to their low adoption, though with large patient pool. The Middle East & Africa to adopt this advanced technology lately due to less awareness and less reach of the product due to less geographical presence of the players.
Examples of some of the key participants in the non-union fractures market are Daniel C. Allison, Regenexx, Kalytera Therapeutics, Inc., ASA srl, Mesentech, EnteraBio Ltd. and others.
Key data points covered in report
The report covers exhaustive analysis on:
By Product Type
By Application Type
By End User
The market sizing of the non-union fractures market will be done by the adoption data triangulation approach. Demand-side approach will be followed to assess the actual market size of non-union fractures. Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product offerings, usage pattern as per disease indications, product installed base in target healthcare facilities, life span of a device, reimbursement scenario, adoption rate and future impact of new technologies.
Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, and supply-side providers of medical devices who provide valuable insights on trends, key treatment patterns, adoption rate, and purchasing pattern, technological development of medical devices, patient education, effectiveness of manufacturers and important strategies, pricing and competitive dynamics.
Non-Union Fractures Market to be driven by the non-fractured mindset in the UK and US
As per Persistence Market Research, the global non-union fractures market is expected to display vertical growth between 2020 and 2030.
Non-union fracture does show resemblance on structural front with fibrous joint, better known as pseudoarthrosis. Poor blood supply hampers the healing of bone. False joint also needs to be addressed. The number of non-union fractures is rising day after day. The UK alone witnesses 850,000 novel bone fractures every year. This factor is expected to catalyse the market going forward.
The outbreak of Covid-19 has resulted either in annulment or delay in treatment related to non-union fractures due to partial/total lockdowns enforced all across. This scenario is bound to continue till mid-2021 (till Covid-19 vaccine would probably be in place).
Research states that close to 50 Mn bone fractures do occur at the global level on a consistent basis. The main reason behind bone fractures is osteoporosis. Moreover, around 33% of femoral shaft fractures and tibia end up getting unreported. This postponement does result in poorer rates of recuperation.
As of now, Europe and North America collectively account for the largest market share owing to growing awareness regarding treatment options. Stem cell therapy is also contributing to the growth of non-union fractures market. Teriparatide is the morphogenetic protein looked upon as a remedial/therapeutic choice on the count of non-union fractures.
At the same time, it needs to be noted that the Asia-Pacific would slow down in terms of growth due to pretty low adoption. Lack of awareness is the basic reason behind low adoption. MEA will also be show a sluggish rate of adoption.
The key players in the non-union fractures market include Daniel C. Allis, Kalytera Therapeutics, Inc., EnteraBio Ltd., Mesentech, ASA srl, and Regenexx. He players are concentrating on both – organic and inorganic mode of growth to gain a competitive edge over one another.